Tuesday December 12, 2017 19:07

JANSSEN Press Releases

Janssen to Discontinue Hepatitis C Development Program Heathcare—11 Sep 17

- Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational

Photo Release: ARTIST PLAYGROUND BY PULLMAN AT PULLMAN BANGKOK GRANDE General—16 Mar 17

With the concept 'Artist Playground by Pullman' Mr.Patrick Janssen (left)-Hotel Manager of Pullman Bangkok Grande Sukhumvit recently welcomed Mr.Josh Roxas (right), multi-award-winning Filipino artist, in the launching of Coloured Cities art gallery. The

พิพิธภัณฑ์ Dr. Guislain (Dr. Guislain Museum) และ Janssen รับสมัครการเสนอชื่อเพื่อเข้ารับรางวัล สุขภาพ—10 Mar 17

- โอกาสที่จะให้รางวัลกับผู้ที่ต้องการจะสร้างความแตกต่างสำหรับบุคคลที่มีความเจ็บป่วยทางจิต - พิพิธภัณฑ์ Dr. Guislain ในเมืองเก้นท์ ประเทศเบลเยียม และ บริษัท Janssen Research & Development, LLC ("Janssen") ประกาศวันนี้ว่า

Dr. Guislain Museum and Janssen Seek Nominations for 2017 Breaking the Chains of Stigma Heathcare—10 Mar 17

The Dr. Guislain Museum in Ghent, Belgium and Janssen Research & Development, LLC ("Janssen"), today announced that they are seeking nominations for the sixth annual Dr. Guislain "Breaking the Chains of Stigma" Award. The Award honors an individual,

Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Heathcare—14 Feb 17

- First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression Janssen Sciences Ireland UC

Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the Heathcare—31 Mar 16

- Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens Janssen Sciences Ireland UC and certain Janssen affiliates* today announced it will present thirteen abstracts featuring new data on an investigational regimen

First Regimen Combining Long Acting Injectable Antir 32-Week LATTE 2 Study Results Presented at Heathcare—24 Feb 16

- Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity todaily oral 3-drug combination Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) announced 32-week data

Dr. Guislain Museum and Janssen Research Development, LLC Launch International Call for Heathcare—02 Feb 16

The Dr. Guislain Museum in Ghent, Belgium and Janssen Research & Development, LLC ("Janssen"), today announced the opening of the call for nominations period for the fifth annual Dr. Guislain "Breaking the Chains of Stigma" Award. The Award honors an

Dr. Guislain Museum และ Janssen Research Development, LLC เปิดรับสมัครผู้เข้าชิงรางวัล Dr. สุขภาพ—02 Feb 16

พิพิธภัณฑ์ Dr. Guislain Museum ในเมืองเกนต์ ประเทศเบลเยี่ยม จับมือกับบริษัท Janssen Research & Development, LLC ขอเชิญชวนบุคคลและองค์กรทั่วโลกเสนอชื่อเข้าชิงรางวัล Dr. Guislain "Breaking the Chains of Stigma" ประจำปีครั้งที่ 5

ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Heathcare—08 Jan 16

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of the

Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Heathcare—08 Jan 16

Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV

Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Heathcare—21 Dec 15

Janssen Pharmaceuticals, Inc. (Janssen) announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN(R) technology, jointly with Janssen's own AdVac(R) technology, in the

New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Heathcare—19 Nov 15

Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine (NEJM) will publish findings from a respiratory syncytial virus (RSV) challenge study for ALS-008176, a cytidine nucleoside analog with

First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Heathcare—04 Nov 15

Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that Phase IIb data

Museum Dr. Guislain ร่วมกับ Janssen ขอเชิญชวนบุคคลและองค์กรทั่วโลกเสนอชื่อเข้าชิงรางวัล Dr. Heathcare—10 Mar 15

พิพิธภัณฑ์ Museum Dr. Guislain ในเมืองเกนต์ ประเทศเบลเยียม และบริษัท Janssen Research & Development, LLC ("Janssen") ประกาศเชิญชวนบุคคลและองค์กรทั่วโลกเสนอชื่อเข้าชิงรางวัล Dr. Guislain "Breaking the Chains of Stigma" Award ประจำปี ครั้งที่ 4

Museum Dr. Guislain and Janssen Research Development, LLC Issue Global Call for Nominations for Heathcare—10 Mar 15

The Museum Dr. Guislain in Ghent, Belgium, and Janssen Research & Development, LLC ("Janssen") today announced they are seeking nominations for the fourth annual Dr. Guislain "Breaking the Chains of Stigma" Award. The award honours an individual,

Janssen Announces Collaboration with Gilead to Develop PREZISTA(R)-based Single-tablet Regimen for Heathcare—30 Dec 14

-- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed as Eviplera(R) in the European Union -- Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc.

อีบี ฟาร์มา ทำสัญญาขออนุญาตใช้สิทธิ์ยา Tipifarnib จากแจนเซ่น ฟาร์มาซูติกา สุขภาพ—24 Dec 14

อีบี ฟาร์มา แอลแอลซี (EB Pharma, LLC.) บริษัทในเครือของไอเกอร์ ไบโอฟาร์มาซูติคัลส์ อิงค์ (Eiger BioPharmaceuticals, Inc.) ประกาศว่า บริษัทได้บรรลุข้อตกลงกับแจนเซ่น ฟาร์มาซูติกา เอ็นวี (Janssen Pharmaceutica NV) ในการขออนุญาตใช้สิทธิ์ยา Tipifarnib

EB Pharma Announces License Agreement for Investigational Drug, Tipifarnib from Janssen Heathcare—24 Dec 14

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., today announced that it has executed an agreement with Janssen Pharmaceutica NV, ("Janssen"), for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza Heathcare—19 Jun 14

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Heathcare—12 Jun 14

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine

Janssen ประกาศจัดตั้งกลุ่ม Janssen GPH ตั้งเป้าตอบสนองความต้องจากที่แท้จริง ทั่วไป—24 Jan 14

- Janssen Global Public Health จะดูแลงานวิจัยและพัฒนา ตลอดจนการพัฒนาเชิงกลยุทธ์ เพื่อคิดค้นผลิตภัณฑ์ยาที่ได้มีการแปรรูป Janssen บริษัทด้านเภสัชกรรมของ Johnson & Johnson ประกาศจัดตั้ง Janssen Global Public Health (Janssen GPH) ซึ่งเป็นกลุ่มธุรกิจใหม่

Janssen Announces New Group Targeting Unmet Global Health Needs General—24 Jan 14

- Janssen Global Public Health to Oversee R&D and Access Strategy Development for Growing Portfolio of Transformational Medicines Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public

Janssen Submits Marketing Authorisation Application to European Medicines Agency for a Fixed-Dose General—15 Oct 13

Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing

Janssen RD Ireland Announces Agreement with PATH for Early Development of Rilpivirine in General—25 Sep 13

Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential

พิพิธภัณฑ์ Museum Dr. Guislain และบริษัท Janssen R&D ประกาศรับสมัครผู้เข้าชิงรางวัล Dr. Guislain General—25 Jan 13

พิพิธภัณฑ์ Museum Dr. Guislain ในเมืองเกนต์ ประเทศเบลเยียม ซึ่งได้รับการสนับสนุนจากบริษัท Janssen Research & Development, LLC ประกาศรับสมัครผู้เข้าชิงรางวัล Dr. Guislain “Breaking the Chains of Stigma” Award ประจำปี 2556

Museum Dr. Guislain and Janssen R&D Issue 2013 Dr. Guislain "Breaking the Chains of Stigma" Award General—25 Jan 13

Today, Museum Dr. Guislain in Ghent, Belgium, with support from Janssen Research & Development, LLC ("Janssen"), announced they have issued a global call for nominations for the 2013 Dr. Guislain "Breaking the Chains of Stigma" Award. The award honors an

MasterCard names Debra Janssen MD, Access Prepaid Worldwide Stcoks—15 Aug 11

Purchase, New York, August 15th, 2011 – MasterCard Worldwide today announced that Debra Janssen has been appointed managing director of MasterCard’s Access Prepaid Worldwide subsidiary, effective immediately. As managing director, Janssen